Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts. Show more

Location: 225 Franklin Street, Boston, MA, 02110, United States | Website: https://ateapharma.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

278.5M

52 Wk Range

$2.46 - $4.14

Previous Close

$3.51

Open

$3.51

Volume

360,220

Day Range

$3.46 - $3.56

Enterprise Value

-99.92M

Cash

379.7M

Avg Qtr Burn

-29.22M

Insider Ownership

12.72%

Institutional Own.

71.73%

Qtr Updated

06/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.